The Peptide Shift Has Started
Right now (as of 2026), the FDA is starting to revisit a lot of peptides that were previously restricted, but nothing major has fully changed yet. They’re looking at allowing compounding on a group of peptides (around 12–14), including: - BPC-157 - GHK-Cu - TB-500 - LL-37 - Melanotan II - Dihexa - PEG-MGF All of these are getting attention for things like tissue repair, recovery, antimicrobial effects, and cognition—but most of them still don’t have full FDA-level clinical trials. On the other side, the GLP-1s: - Semaglutide - Tirzepatide Those are already fully FDA-approved and validated for weight loss and metabolic use. There are also newer peptides being developed (like antibiotic-targeting ones), but those are still in early stages. Big picture: - The FDA is considering opening things up - Most of these peptides are still in a restricted category right now - Compounding isn’t officially allowed on most of them yet - More decisions are expected (meetings through 2026–2027) So overall: Things are moving, but we’re not there yet.